CervoMed Inc (CRVO)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$1.45-7.05%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · CRVO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -77.5% |
| Our one-year growth estimate | diamond | -70.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 7.6 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
CRVO — capital allocation — Unregistered Sales of Equity Securities
Dated 2026-06-22
Unregistered Sales of Equity Securities. The information set forth in
Why it matters: CervoMed has named a partner as its path to a DLB Phase 3 trial. No partner or trial start is reported in these inputs.
Supportive ifCervoMed names a strategic partner and confirms funding or a start plan for a DLB Phase 3 trial.
Worry ifCervoMed reports no partner or Phase 3 funding, or says the DLB trial plan has been delayed.
Why it matters: The last DLB trial missed its main goal in the full group. CervoMed links that result to low drug levels and plans a new dose.
Watch forA future DLB trial uses the 100 mg twice-daily tablet. It reports trough drug levels near or above 4 ng/mL and meets its stated main clinical goal.
Also watch forA future DLB trial uses the 100 mg twice-daily tablet. It fails its stated main clinical goal, or most participants have trough levels below 4 ng/mL.
Why it matters: The 12-week trial showed a mean NfL drop of about 3.1 pg/mL. The 24-week data can show if that change lasts.
Watch forAt CTAD, mean NfL stays below baseline at week 24. The drop is larger in participants whose starting NfL was at or above the median.
Also watch forAt CTAD, mean NfL returns to or rises above baseline by week 24.
Why it matters: The reported cash plan runs through Q3 2027. A shorter runway could make it harder to fund trials and a DLB partner plan.
Worry ifA company filing says cash and marketable securities fall short of planned expenses through September 2027. Or it gives a runway date before Q3 2027.
Less concerning ifA company filing reports enough cash for planned expenses through Q3 2027 or later. It discloses no need for new funding.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$247 on $10,000 · ±2.5% | How much price usually moves either way. |
| Bad day | $984 loss on $10,000 · 9.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,541 loss on $10,000 · 85.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.